ILLUMINA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 110.4 USD | -0.19% |
|
-11.10% | -20.83% |
| May. 07 | Illumina Files Registration Statement for Planned GRAIL Divestiture | MT |
| May. 03 | Bernstein Adjusts Illumina's Price Target to $130 From $129 | MT |
Presenter SpeechUnknown Attendee (Attendees)Good morning. Please welcome to the stage Vice Pre...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
110.6
USD
Average target price
156.1
USD
Spread / Average Target
+41.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.72% | 17.62B | |
| +8.71% | 219B | |
| +8.22% | 185B | |
| +14.51% | 135B | |
| +27.86% | 107B | |
| +14.61% | 51.28B | |
| +4.48% | 51.01B | |
| +4.04% | 41.85B | |
| +6.38% | 37.02B | |
| +25.56% | 31.27B |
- Stock Market
- Equities
- ILMN Stock
- News Illumina, Inc.
- Transcript : Illumina, Inc. - Analyst/Investor Day